Moderna, Inc. (NASDAQ:MRNA) CEO Sells $1,064,430.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 30th. The shares were sold at an average price of $118.27, for a total value of $1,064,430.00. Following the completion of the transaction, the chief executive officer now owns 6,514,868 shares of the company’s stock, valued at $770,513,438.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Stephane Bancel also recently made the following trade(s):

  • On Monday, December 28th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $116.44, for a total value of $1,286,196.24.
  • On Wednesday, December 23rd, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $120.00, for a total value of $1,080,000.00.
  • On Monday, December 21st, Stephane Bancel sold 4,729 shares of Moderna stock. The stock was sold at an average price of $141.12, for a total value of $667,356.48.
  • On Friday, December 18th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $139.60, for a total value of $1,542,021.60.
  • On Wednesday, December 16th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $137.51, for a total value of $1,237,590.00.
  • On Friday, December 11th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $159.18, for a total value of $1,758,302.28.
  • On Wednesday, December 9th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $170.00, for a total value of $1,530,000.00.
  • On Friday, December 4th, Stephane Bancel sold 21,046 shares of Moderna stock. The stock was sold at an average price of $148.11, for a total value of $3,117,123.06.
  • On Tuesday, December 1st, Stephane Bancel sold 3,929 shares of Moderna stock. The stock was sold at an average price of $178.00, for a total value of $699,362.00.
  • On Friday, November 27th, Stephane Bancel sold 21,046 shares of Moderna stock. The stock was sold at an average price of $119.23, for a total value of $2,509,314.58.

MRNA stock opened at $104.47 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.43 and a quick ratio of 2.43. The stock has a market capitalization of $41.34 billion, a price-to-earnings ratio of -64.49 and a beta of 1.84. The business’s fifty day moving average price is $125.92 and its two-hundred day moving average price is $83.44. Moderna, Inc. has a fifty-two week low of $17.68 and a fifty-two week high of $178.50.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.16). The firm had revenue of $157.90 million for the quarter, compared to the consensus estimate of $82.50 million. Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The firm’s quarterly revenue was up 828.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.37) EPS. Research analysts expect that Moderna, Inc. will post -1.77 EPS for the current year.

A number of equities research analysts have recently issued reports on the company. Morgan Stanley cut Moderna from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $100.00 to $150.00 in a research note on Wednesday, December 16th. BidaskClub upgraded Moderna from a “hold” rating to a “buy” rating in a research note on Thursday, September 17th. Jefferies Financial Group cut Moderna from a “buy” rating to a “hold” rating and upped their price objective for the stock from $90.00 to $150.00 in a research note on Tuesday, December 15th. Barclays upped their price objective on Moderna from $84.00 to $169.00 and gave the stock an “overweight” rating in a research note on Friday, December 18th. Finally, Wells Fargo & Company upped their price objective on Moderna from $92.00 to $129.00 and gave the stock an “equal weight” rating in a research note on Monday, November 30th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $124.84.

A number of hedge funds have recently bought and sold shares of the business. FMR LLC increased its position in Moderna by 51.6% during the 2nd quarter. FMR LLC now owns 37,532,143 shares of the company’s stock worth $2,409,938,000 after buying an additional 12,772,752 shares during the period. Vanguard Group Inc. increased its position in Moderna by 24.5% during the 2nd quarter. Vanguard Group Inc. now owns 25,625,532 shares of the company’s stock worth $1,645,416,000 after buying an additional 5,045,279 shares during the period. BlackRock Inc. increased its position in Moderna by 2.1% during the 3rd quarter. BlackRock Inc. now owns 20,236,765 shares of the company’s stock worth $1,431,750,000 after buying an additional 412,616 shares during the period. State Street Corp grew its holdings in shares of Moderna by 9.2% during the 3rd quarter. State Street Corp now owns 6,583,927 shares of the company’s stock worth $465,813,000 after purchasing an additional 556,953 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Moderna by 43.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,456,015 shares of the company’s stock worth $93,491,000 after purchasing an additional 438,140 shares in the last quarter. Hedge funds and other institutional investors own 53.06% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: What are the benefits of investing in REITs?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.